{"nctId":"NCT03004248","briefTitle":"Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines","startDateStruct":{"date":"2016-12-09","type":"ACTUAL"},"conditions":["Glabellar Frown Lines"],"count":2691,"armGroups":[{"label":"DaxibotulinumtoxinA 40 units","type":"EXPERIMENTAL","interventionNames":["Biological: Botulinum Toxins, Type A"]}],"interventions":[{"name":"Botulinum Toxins, Type A","otherNames":["DaxibotulinumtoxinA"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provide written informed consent including authorization to release health information\n* Moderate (2) or severe (3) glabellar lines during maximum frown based on the Investigator Global Assessment Frown Wrinkle Severity (IGA-FWS) scale\n* Moderate (2) or severe (3) glabellar lines during maximum frown based on the Patient Frown Wrinkle Severity (PFWS) scale\n* Willing and able to follow all trial procedures, attend all scheduled visits, and successfully complete the trial\n\nExclusion Criteria:\n\n* Any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type A, including peripheral motor neuropathic diseases such as amyotrophic lateral sclerosis and motor neuropathy, and neuromuscular junctional disorders such as Lambert-Eaton syndrome and myasthenia gravis\n* Active skin disease, infections or inflammation at the injection sites\n* Plan to receive botulinum toxin type A anywhere in the face through the duration of the study\n* History of allergy or sensitivity to any botulinum toxin preparations or to any component of the test article\n* Current enrollment in an investigational drug or device trial or participation in such a trial within the last 30 days prior to screening through end of trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Treatment Emergent Adverse Events (TEAE)","description":"Incidence rates based on the number and percentage of subjects treated within each cycle who report Adverse Events (AEs) at anytime following study treatment. Note that subjects could receive up to 3 consecutive treatments during the 36-week follow up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"831","spread":null},{"groupId":"OG001","value":"267","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Achieved â‰¥ 2 Point Improvement Independently and Concurrently on Investigator and Patient Rating Scales","description":"Percentage of subjects who achieve at least a 2-point improvement from baseline and a score of 0 or 1 (i.e. none or mild wrinkles in severity) on both Investigator and Subject Frown Wrinkle Severity (FWS) assessments","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.2","spread":null},{"groupId":"OG001","value":"76.8","spread":null},{"groupId":"OG002","value":"76.6","spread":null}]}]}]},{"type":"SECONDARY","title":"The Time to Return to Moderate to Severe on Both IGA-FWS and PFWS Scales for DaxibotulinumtoxinA for Injection Group","description":"The time to return to moderate to severe on both scales was measured following treatment cycles 1 and 2. Because subjects were only followed for 12 weeks following treatment cycle 3, time to return was not analyzed for this cycle.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"168.0","spread":null},{"groupId":"OG001","value":"169.0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Time to Return to, or Worse Than, Baseline on Both IGA-FWS and PFWS Scales for DaxibotulinumtoxinA for Injection Group","description":"The time to return to or worse than baseline on both FWS scales was measured following treatment cycles 1 and 2. Because subjects were only followed for 12 weeks following treatment cycle 3, time to return was not analyzed in this cycle.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"196","spread":null},{"groupId":"OG001","value":"197","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":29,"n":2691},"commonTop":["Headache"]}}}